首页 > 市场调查报告书 > 製药

自体免疫疾病

市场调查报告书

商品编码

1616797

自体免疫疾病诊断市场机会、成长动力、产业趋势分析与预测 2024 - 2032

Autoimmune Disease Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

出版日期: 2024年09月18日 | 出版商:

Global Market Insights Inc. | 英文 190 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023年，全球自体免疫疾病诊断市场估值为53亿美元，预计2024年至2032年复合年增长率为5.9%。的日益采用推动的。当免疫系统因潜在的异常而错误地攻击人体细胞时，就会出现自体免疫疾病。当免疫系统无法辨识其细胞时，就会发生这种故障，导致产生针对健康组织的自身抗体。为了解决这个问题，各个组织正在实施倡议，以提高对自体免疫疾病及其社会经济影响的认识。

这些努力导致全球对诊断测试的需求更高。此外，实验室自动化和技术的进步有助于自体免疫疾病诊断领域的发展。市场按产品类型分类，特别是试剂、消耗品和仪器。试剂和耗材领域占据最大的市场份额，到 2023 年将产生约 35 亿美元的收入。

随着需要这些测试的患者人数的增加，对试剂和耗材的需求也相应增加。诊断技术的不断进步，包括酶联免疫吸附测定 (ELISA)、聚合酶链反应 (PCR) 和免疫萤光测定，增加了对专用试剂的需求。依疾病类型划分，市场分为全身性自体免疫疾病及局部自体免疫疾病。局部自体免疫疾病领域在2023 年以约37 亿美元的收入引领市场，预计复合年增长率为5.7%。需要定期进行检查监测和频繁评估。在北美，自体免疫疾病诊断市场到 2023 年将产生 19 亿美元的收入，预计在预测期内将出现显着成长。预计到2030 年，光是美国市场就将超过29 亿美元。行业参与者的存在。随着意识和技术的发展，自体免疫疾病诊断市场有望强劲成长。

市场范围
开始年份	2023年
预测年份	2024-2032
起始值	53亿美元
预测值	90 亿美元
复合年增长率	5.9%

。

产业生态系统分析
产业影响力
- 成长动力
  - 自体免疫疾病的高发生率和盛行率
  - 人们对自体免疫疾病的认识不断提高
  - 政府对自体免疫疾病研究活动的支持政策
  - 技术进步和实验室自动化技术的日益采用
- 产业陷阱与挑战
  - 设立诊断中心需要大量资金投入
  - 测试结果週转时间慢并且需要进行多次诊断测试
成长潜力分析
技术景观
未来市场趋势
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按产品分类，2021 - 2032 年

主要趋势
试剂及耗材
仪器仪表

第 6 章：市场估计与预测：按疾病类型，2021 - 2032

主要趋势
系统性自体免疫疾病
- 类风湿关节炎
- 系统性红斑狼疮（SLE）
- 牛皮癣
- 多发性硬化症
- 其他系统性自体免疫疾病
局限性自体免疫疾病
- 发炎性肠道疾病
- 1 型糖尿病
- 甲状腺
- 其他局部自体免疫疾病

第 7 章：市场估计与预测：按测试类型，2021 - 2032

主要趋势
抗核抗体测试
自体抗体测试
C反应蛋白（CRP）
全血球计数 (CBC)
尿液分析
其他测试

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

主要趋势
医院
诊断中心
其他最终用户

第 9 章：市场估计与预测：按地区划分，2021 - 2032 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 10 章：公司简介

Abbott Laboratories
Bio-rad Laboratories, Inc.
DIAsource ImmunoAssays SA
Euroimmun AG (Perkin Elmer)
F. Hoffmann-la Roche Ltd.
Hemagen Diagnostics
Myriad Genetics
Quest Diagnostics
Siemens Healthineers Inc.
SQI Diagnostics Inc.
Thermo Fisher Scientific Inc.
Trinity Biotech Plc.

简介目录

Product Code: 618

The Global Autoimmune Disease Diagnostics Market was valued at USD 5.3 billion in 2023 and is projected to grow at a CAGR of 5.9% from 2024 to 2032. This growth is primarily driven by the increasing prevalence of autoimmune disorders and the growing adoption of automated diagnostic equipment. Autoimmune diseases arise when the immune system erroneously attacks the body's cells due to underlying abnormalities. This malfunction can occur when the immune system fails to recognize its cells, leading to the production of autoantibodies that target healthy tissues. To combat this issue, various organizations are implementing initiatives to enhance awareness of autoimmune diseases and their socioeconomic implications.

These efforts are resulting in a higher demand for diagnostic tests worldwide. Furthermore, advancements in laboratory automation and technology contribute to the growth of the autoimmune disease diagnostics sector. The market is categorized by product types, specifically reagents and consumables and instruments. The reagents and consumables segment held the largest market share, generating approximately USD 3.5 billion in revenue in 2023. This segment's growth is fueled by the rising number of autoimmune diseases, leading to an increased need for diagnostic testing.

As the patient population requiring these tests grows, the demand for reagents and consumables rises correspondingly. Continuous advancements in diagnostic technologies, including enzyme-linked immunosorbent assays (ELISA), polymerase chain reaction (PCR), and immunofluorescence assays, have created a heightened need for specialized reagents. When examined by disease type, the market is divided into systemic autoimmune diseases and localized autoimmune diseases. The localized autoimmune disease segment led the market with revenues of around USD 3.7 billion in 2023, and it is expected to experience a CAGR of 5.7%.The high prevalence of localized autoimmune disorders drives the demand for diagnostic testing, as these conditions often necessitate regular monitoring and frequent assessments. In North America, the autoimmune disease diagnostics market generated USD 1.9 billion in revenue in 2023, and significant growth is anticipated over the forecast period. The U.S. market alone is expected to exceed USD 2.9 billion by 2030. This substantial market share can be attributed to several factors, including the rising burden of autoimmune diseases, increased healthcare spending, new product launches, and the presence of key industry players in the region. As awareness and technology evolve, the market for autoimmune disease diagnostics is poised for robust growth.

Market Scope
Start Year	2023
Forecast Year	2024-2032
Start Value	$5.3 Billion
Forecast Value	$9 Billion
CAGR	5.9%

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 High incidence and prevalence of autoimmune diseases
  - 3.2.1.2 Growing awareness about autoimmune diseases
  - 3.2.1.3 Supportive government policies for research activities on autoimmune diseases
  - 3.2.1.4 Technological advancements and increasing adoption of lab automation technologies
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Need for high capital investment in setting-up diagnosis centers
  - 3.2.2.2 Slow turnaround time for test results and need for multiple diagnostic tests
3.3 Growth potential analysis
3.4 Technology landscape
3.5 Future market trends
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Reagents and consumables
5.3 Instruments

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Systemic autoimmune disease
- 6.2.1 Rheumatoid arthritis
- 6.2.2 Systemic lupus erythematosus (SLE)
- 6.2.3 Psoriasis
- 6.2.4 Multiple sclerosis
- 6.2.5 Other systemic autoimmune diseases
6.3 Localized autoimmune disease
- 6.3.1 Inflammatory bowel disease
- 6.3.2 Type 1 diabetes
- 6.3.3 Thyroid
- 6.3.4 Other localized autoimmune diseases

Chapter 7 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Antinuclear antibody tests
7.3 Autoantibody tests
7.4 C-reactive protein (CRP)
7.5 Complete blood count (CBC)
7.6 Urinalysis
7.7 Other tests

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospitals
8.3 Diagnostics centers
8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa